强直性脊柱炎患者死亡率与治疗方式的全国回顾性队列研究
基于以色列最大健康维护组织电子数据库的回顾性队列研究,纳入2002至2018年诊断的5930例强直性脊柱炎(AS)患者及29018名匹配对照,中位随访7.5年。AS患者死亡率较对照升高(年龄性别调整HR 1.19,95%CI 1.10-1.30),但接受TNFi治疗者与对照无显著差异。AS队列内年龄、男性、基线合并症及平均CRP水平为死亡预测因素。
要点
- AS患者年龄性别调整后死亡风险较一般人群升高19%(HR 1.19)。
- 接受TNFi治疗的AS患者死亡率与匹配对照无显著差异。
- AS队列内年龄、男性、合并症及较高CRP为死亡风险因素。
核心结论
- AS患者较一般人群死亡风险升高,调整年龄、性别及基线合并症后仍显著。
- 接受TNFi治疗的AS患者未显示较匹配对照的额外死亡风险。
- AS队列内年龄、男性、基线合并症及较高平均CRP水平为死亡风险因素。
研究设计与样本
- 回顾性队列研究,使用以色列最大健康维护组织电子数据库。
- 纳入2002至2018年诊断的所有AS患者,对照按年龄、性别、诊所及入组时间匹配。
- 随访至死亡或研究结束,中位随访7.5年。
- 共5930例AS患者和29018名匹配对照。
主要发现
- AS队列死亡667例,对照死亡2919例;平均死亡年龄分别为76.9岁和77.1岁(P=0.74)。
- 3249例(54.8%)AS患者仅用NSAIDs,1760例(29.7%)用TNFi,1687例(28.4%)用DMARDs。
- AS患者较对照死亡风险升高,年龄性别调整HR 1.19(95%CI 1.10-1.30)。
- 男性HR 1.15(95%CI 1.04-1.27),女性HR 1.32(95%CI 1.13-1.54);调整基线合并症后HR 1.14(95%CI 1.05-1.24)。
- TNFi单药HR 0.67(95%CI 0.38-1.18),TNFi联合DMARDs HR 0.93(95%CI 0.69-1.25),与对照无显著差异。
关键数值与推荐
- AS患者年龄性别调整死亡HR 1.19(95%CI 1.10-1.30)。
- 男性AS患者死亡HR 1.15(95%CI 1.04-1.27),女性HR 1.32(95%CI 1.13-1.54)。
- 调整基线合并症后AS患者死亡HR 1.14(95%CI 1.05-1.24)。
- TNFi治疗者HR 0.67(95%CI 0.38-1.18),TNFi联合DMARDs者HR 0.93(95%CI 0.69-1.25)。
临床怎么用
- 对AS患者应关注年龄、男性、合并症及CRP水平等死亡风险因素。
- TNFi治疗与未增加的死亡风险相关,支持其在AS中的使用。
- 需结合合并症管理以降低AS患者死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this large population-based study we aimed: 1) to assess mortality in patients with ankylosing spondylitis (AS) compared to the general population, considering demographics, comorbidities, and treatment, and 2) to assess factors associated with mortality within patients with AS. METHODS: This study was designed as a retrospective cohort study using the electronic database of the largest health maintenance organization in Israel. All patients with AS diagnosed between 2002 and 2018 were included. Controls were matched by age, sex, clinic, and enrollment time. Follow-up continued until death or the end of the study. RESULTS: The study comprised 5,930 AS patients and 29,018 matched controls who were followed up for a median period of 7.5 years. There were 667 deaths within the AS cohort and 2,919 deaths within controls; the mean age at death was 76.9 years and 77.1 years, respectively (P = 0.74). A total of 3,249 AS patients (54.8%) were treated only with nonsteroidal antiinflammatory drugs, 1,760 (29.7%) were treated with tumor necrosis factor inhibitors (TNFi), and 1,687 (28.4%) with disease-modifying antirheumatic drugs (DMARDs). Mortality rates were increased among AS patients compared to controls, with an age- and sex-adjusted hazard ratio (HR) of 1.19 (95% confidence interval [95% CI] 1.10-1.30). The association was significant for men (HR 1.15 [95% CI 1.04-1.27]) and women (HR 1.32 [95% CI 1.13-1.54]), and after adjusting for background comorbidities (HR 1.14 [95% CI 1.05-1.24]). AS patients treated with TNFi or with a combination of TNFi and DMARDs did not have significant difference in mortality rates compared to controls (HR 0.67 [95% CI 0.38-1.18] and HR 0.93 [95% CI 0.69-1.25], respectively). Age, male sex, mean C-reactive protein (CRP) levels and general comorbidities were predictors of mortality within the AS cohort. CONCLUSION: AS patients had an increased mortality risk compared to the general population after adjusting for age, sex, and baseline comorbidities. AS patients treated with TNFi did not demonstrate excess mortality compared to matched controls. Within the AS cohort, age, male sex, background comorbidities, and higher CRP levels were identified as risk factors for mortality.
引用
- Ben-Shabat N, Shabat A, Watad A, et al. Mortality in Ankylosing Spondylitis According to Treatment: A Nationwide Retrospective Cohort Study of 5,900 Patients From Israel. Arthritis Care Res (Hoboken). 2022. PMID: 33973404. doi:10.1002/acr.24616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。